Novartis/Penn To Research Chimeric Antigen Receptor Immunotherapies
This article was originally published in The Pink Sheet Daily
The Anglo/Swiss pharma will work with University of Pennsylvania researchers to discover, develop and commercialize CAR immunotherapy drugs for cancer, while also establishing a joint R&D facility at the Philadelphia campus.
You may also be interested in...
By licensing Spark Therapeutics' Luxturna outside the US, Novartis is expanding its gene therapy ambitions into in vivo and non-oncological treatments.
Emerging data for the immunotherapy class continues to impress, and investigators at the American Society of Hematology report success with managing the cytokine-release syndrome side effects.
Servier inks its second deal in less than two weeks, this time for potential diabetes candidates. While both deals are early, they mark the French biotech’s foray into two hot fields of research.